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1. INTRODUCTION
The WHO Collaborating Centres for Arboviruses and Haemorrhagic Fevers represents 
a unique, global resource composed of internationally recognized centres of excellence* 
While these laboratories direct their specific activities on viral diseases, they are often 
associated with national reference centres and Ministries of Health, so that they and 
their host institutions may be at the fore of current local and regional public health 
issues in many fields* These combined resources could contribute to the solution of 
global problems, not only of viral diseases, but also a number of other non-viral 
illnesses. It is with this potential in mind that we have organized a meeting of the 
Directors, not only to discuss arboviruses and haemorrhagic fevers, but also to explore 
the possible contribution of this network to the solution of the larger problem of 
emerging diseases, many of which are viral in nature. The past decade has witnessed 
diminished activity on the part of WHO to make maximum use of this network of 
Collaborating Centres, and clearly their full potential value as a dynamic, interactive 
network has not been attained. We hope that through this initial meeting, we can 
stimulate increased communications and collaborations, exchanges of information and 
technical resources, and enlist the Director's support in systematically addressing 
emerging diseases on a global scale.
Considerable attention has recently been focused on the problem of emerging infectious 
diseases. This interest was generated by the current pandemic of HIV and AIDS, but 
has its origin in the fundamental observations that microorganisms continually mutate, 
that human demographics and social standards change, and that the global environment 
is being modified. Ever-increasing movement of live animals and animal products, and 
changing land use are altering and expanding the geographic distribution of animal 
diseases, including zoonoses. Antibiotic resistance in bacteria continues to develop, 
leading to reduced effectiveness, increased health care costs, and needless human 
suffering and death when ineffective drugs are prescribed. These conditions necessitate 
that a coordinated, global approach be developed to systematically address emerging 
diseases.
2. BACKGROUND
During the past decade, numerous emerging and re-emerging infectious diseases have 
been recognized. In addition to HIV and AIDS, dengue haemorrhagic fever 
dramatically invaded the Americas, causing a massive outbreak in Cuba in 1981* More 
recently, dengue haemorrhagic fever has been documented in Brazil and Venezuela, 
and threatens other Latin American nations, as well as Asian and Pacific countries, 
including Australia, where dengue transmission was recently recorded in northeastern 
parts of the country for the first time in decades. Pandemic cholera reappeared in 
South America in 1991 after that region was cholera-free for many years, and a new 
cholera strain, V. cholerae 0139, which appears to avoid the protective immunity of 
persons previously infected with other strains of cholera, emerged in the Indian 
subcontinent. In Russia, diphtheria has made a dramatic resurgence in 1991 to 1993, 
and in Africa, epidemic yellow fever was recognized for the first time in Kenya. Rift 
Valley fever virus, an important pathogen of both domestic animals and humans, was 
documented in Egypt the first time since the devastating outbreak of 1977-1978, when
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thousands of animals and humans were infected* Elsewhere in Africa, Lassa fever 
continues to cause epidemics, including nosocomial outbreaks with fatalities in doctors 
and nurses; and in the United States, a highly fatal form of hantavirus infection, a 
rodent-borne zoonosis, was recognized for the first time ever* This disease, with a 
clinical presentation of acute pulmonary syndrome leading to death in from 50 to 75% 
of those affected, is perhaps the best example of both a dramatic new disease, and of 
how well prepared laboratory and epidemiological investigations can be quickly 
mobilized to define and combat an emerging infectious disease problem.
3* OBJECTIVES OF MEETING
The meeting of Directors of WHO Collaborating Centres for Arboviruses and 
Haemorrhagic Fevers was convened to re-establish communications within this network 
of laboratories, and to enlist the support of the Directors to collaborate in a global 
response to emerging diseases. This network offers a unique, global resource that could 
play a critical role in these efforts, but due to changing priorities, reduced funding and 
personnel shortages, the Directors of these Centres have not met in more than a 
decade. Clearly the gathering was justified for purposes of rejuvenation, updating and 
coordinating activities alone; however, the need to enlist the support and participation 
of this group in a global programme to address emerging diseases added further 
impetus and a focal point for discussion.
The following objectives were formulated for this meeting:
3.1 To offer directors of WHO Collaborating Centres for Arboviruses and 
Haemorrhagic Fevers an opportunity to meet and exchange information 
regarding recent activities, programmes and capabilities.
3 2  To present results of a questionnaire distributed to Centre Directors regarding 
technical capabilities, so that common technologies, resources and short comings 
may be identified* This information will be used to coordinate future network 
activities and facilitate technical cooperation and mutual assistance among the 
Centres as appropriate.
3.3 To introduce and discuss the problem of emerging diseases.
3.4 To elicit the support of Centre Directors in establishing a coordinated effort to 
address emerging and re-emerging diseases,
3.5 To disseminate information to the Centre Directors regarding existing initiatives 
on emerging diseases, and other relevant surveillance activities of potential 
interest to the group.
4. SUMMARY OF PRESENTATIONS
A total of 11 formal presentations was made on various topics of general interest to the 
group. In addition, five panel discussions were held during which Directors of WHO 
Collaborating Centres of different geographic areas (Americas, Africa, Asia and 
Australia, and Europe) briefly summarized recent activity and discussed common issues. 
A final panel group was composed of leaders from governments and private
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organizations and representatives of the WHO Regional Offices, to discuss global 
surveillance for new, emerging and re-emerging diseases.
Following welcoming remarks by Dr James Hughes, Director, the National Center for 
Infectious Diseases, CDC, Dr Ruth Berkelman discussed emerging infections and the 
role of global surveillance in their recognition. Her presentation clearly delineated a 
potential, critical role for the WHO Directors of Collaborating Centres for Arboviruses 
and Haemorrhagic Fevers in addressing this issue.
Results of a questionnaire sent to all WHO Collaborating Centres, and those likely to 
become Centres in the near future, were then presented Thirty-five Centres were 
asked about their technical capabilities and routine activities in virology. To briefly 
summarize the findings, about three-quarters of the laboratories were directly 
associated with national Ministries of Health, nearly 60% were closely linked to a 
hospital, all trained students, and 74% currently participated in some sort of 
surveillance system. The most commonly used laboratory procedures were enzyme 
immunoassays (100%), immunofluorescent antibody assays (100%), plaque reduction 
neutralization tests (94%), and haemagglutination inhibition tests (91%). A number 
of other routine serological tests were available in many laboratories as w ell Most 
laboratories had some molecular capabilities, including polymerase chain reaction 
(91%) and western blot (91%), and more than half could clone and sequence nucleic 
acid from specimens* Significant limitations were identified, however, in the availability 
of diagnostic reagents. Among the alphaviruses, only half the laboratories had reagents 
to diagnose chikungunya virus, and 35% had reagents for eastern, western or 
Venezuelan equine encephalitis viruses. For the flaviviruses, only 56% could diagnoses 
yellow fever, and 62% had reagents to diagnose all four serotypes of dengue. Tick- 
borne encephalitis could be diagnosed by 74% of the labs, but West Nile, St Louis 
encephalitis and Japanese encephalitis viruses could be diagnosed by half the 
laboratories or fewer. Pathogenic bunyaviruses could be diagnosed by few laboratories, 
with reagents available in 47% of the laboratories for Crimean-Congo haemorrhagic 
fever, 44% for at least one serotype of hantavirus, 41% for Rift Valley fever, 35% for 
sandfly fever, 18% for California group viruses, and 9% for Oropouche virus. Diagnosis 
of viruses specifically associated with haemorrhagic fever, the arenaviruses and the 
filoviruses, was equally limited, with only about 20-30% of the laboratories able to 
provide confirmation of these diseases. Among other viral diseases, 62% were 
prepared to diagnose HIV, 44% for rabies, 56% for polio, 59% for flu, 56% for 
measles, 62% for hepatitis, and 44% for rotaviruses.
The pattern that appeared from this survey was one of a network of laboratories 
generally well equipped and prepared to diagnose common viral diseases prevalent in 
their own geographic location, but often ill-prepared to diagnose viral diseases common 
in other parts of the world. Thus, sick returning travellers may not have their illness 
properly diagnosed, even if they were infected with a pathogen that was relatively 
common in the area visited. Hence, before this network of laboratories could be relied 
upon to recognized '‘new" or "emerging" disease, we first need to assist them to extend 
their capacity to diagnose "common" illnesses. Since enzyme immunoassays represent 
a technical capability common to all the laboratories, it follows that we should direct 
our efforts of capacity building at providing reagents for use in this test.
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Subsequent presentations were directed toward specific technical issues and included; 
a summary of surveillance and control of Argentine haemorrhagic fever, including a 
discussion of the safety and efficacy testing of the recently developed live, attenuated 
vaccine for this disease; an update of the new hantavirus discovered in the southwestern 
United States, and the disease it causes, Hantavirus Pulmonary Syndrome; and a 
summary of the recent outbreak of yellow fever seen in western Kenya* The global 
spread of dengue and dengue haemorrhagic fever was also discussed, as were existing 
surveillance capabilities in Russia and the newly-independent states* Surveillance 
experts from the Centers for Disease Control provided overviews of two highly 
successful programmes, global surveillance of polio viruses, and the global network of 
influenza surveillance, which might serve as models for future efforts in monitoring 
emerging diseases* The comment was made when referring to participants in the polio 
surveillance efforts, that they were a "group of friends confronting a common problem"* 
This seemed a worthy goal to create for our efforts in addressing emerging diseases.
Finally, representatives of both the US Army and the US Navy summarized their 
networks of overseas laboratories, including a discussion of existing capabilities in 
virology. It was clear from these presentations that US military research laboratories 
are critically important in the overall surveillance programme. Overseas laboratories 
and surveillance efforts of military persons deployed to high risk areas of disease can 
provide important information helpful to global surveillance. Reference laboratories, 
such as the United States Army Medical Research Institute of Infectious Diseases, 
where special high containment capabilities exist, provide invaluable reagents to 
laboratories around the world and assist in other diagnostic efforts. Infectious disease 
programmes at such research institutes should be well funded and integrated into the 
overall surveillance efforts.
Panel discussions composed of groups of the Directors of Centres in the Americas, 
Africa, Asia and Australia, and Europe were also held. Each Director provided brief 
comments regarding their respective laboratory capabilities, issues, and topics of 
greatest interest. Each of these presentations served to demonstrate the diversity of 
public health issues faced by these laboratories, and often the magnitude of specific 
problems. For example, the Centre in the United Kingdom, which serves as a national 
reference laboratory for travel medicine referrals, reported that it diagnosed 
approximately 1000 imported cases of dengue each year* Almost all laboratories 
reported dramatic increases in dengue prevalence in their areas, coupled with 
increasing populations of the primaiy vector mosquito, Aedes aegypti. This was 
especially apparent in India, where both dengue, and the more severe complications, 
dengue haemorrhagic fever and dengue shock syndrome, are increasingly seen. (This 
was followed by private discussion between Dr K. Banerjee* Dr S. Halstead, and others, 
resulting in a decision to organize a special meeting in Pune, India, 7-8 February, 1994, 
to define the problem of dengue in India, and to prepare a strategy to combat it*)
Perhaps the most troubling presentations dealt with the growing concern among 
Directors that the risk of urban transmission of yellow fever was increasing, and many 
laboratories were not prepared to diagnose this disease. This was especially apparent 
in Africa, but also a growing concern in the Americas. Other diseases of concern 
included Rift Valley fever, once again active in Egypt, and increasingly recognized in 
many African countries, and Japanese encephalitis, of growing importance in many 
parts of Asia.
H ie concluding discussions focused on how to organize and coordinate a global 
programme for emerging diseases. Key elements of such a system included having 
adequate technical capabilities to differentiate common from uncommon, thus being 
able to know when a "new" or '’emerging" disease was encountered. Another critical 
component was improved, frequent communications, coupled with a central focal point 
that could distribute information and coordinate activities and responses. Finally, there 
was general agreement that WHO should take a leadership role in attempting to 
respond to this challenge, and the Directors of WHO Collaborating Centres were 
supportive of their active involvement in the effort.
RECOMMEND ATI ONS
5.1 WHO should take a leadership role in emerging diseases, and the WHO 
Collaborating Centres for Arboviruses and Haemorrhagic Fevers should play a 
significant part in implementation of the programme.
5.2 To maximize the contributions of the WHO Collaborating Centres in recognition 
and response to emerging diseases, several specific actions should be initiated:
a. Increase communications between Collaborating Centres and with WHO, 
This could be more frequent letters, telephone calls, facsimile messages, or 
greater use of e-mail, as well as more frequent meetings.
b. Provide diagnostic reagents to WHO Collaborating Centres, with the goal of 
being certain that each WHO Collaborating Centre has the technical 
capability of diagnosing common viral diseases, not only within their own 
area, but also among travellers or others possibly infected elsewhere.
c. To facilitate provision of these diagnostic reagents, make maximum use 
should be made of the existing resources already available at certain WHO 
Collaborating Centres, so that those Centres with expertise in a given disease 
can share their knowledge and reagents with others. Limited funding from 
WHO should be made available to facilitate production and distribution of 
these reagents.
5.3 Yellow fever was clearly recognized as a potentially devastating threat to much 
of Africa and the Americas, and special action is needed to prepare WHO 
Collaborating Centres to rapidly diagnose this disease, should outbreaks occur. 
To accomplish this, WHO should facilitate preparation and distribution of 
diagnostic reagents and other support material as soon as possible.
5.4 Dengue and dengue haemorrhagic fever/dengue shock syndrome are increasingly 
seen in tropical and subtropical countries of the world. WHO Collaborating 
Centres should initiate reporting of cases, especially of dengue haemorrhagic 
fever/dengue shock syndrome, so that the magnitude of the problem becomes 
more apparent. Formal or informal reporting should include copies to WHO 
Regional Offices, WHO Representatives at country level and WHO 
Headquarters to ensure maximum dissemination of information.
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5.5 As outbreaks are recognized by WHO Collaborating Centres, Directors are 
urged to notify WHO as soon as possible, especially if technical assistance is 
required, and to provide brief summaries, following appropriate government 
clearance, to WHO Headquarters for rapid publication in the Weekly 
Epidemiological Record, whenever possible.
5.6 Directors of WHO Collaborating Centres were urged to obtain positive control 
sera, especially sera with high IgM titres, to be shared with other Centres for use 
in diagnostic tests. WHO should provide financial support to offset costs of the 
WHO Collaborating Centres in collecting and processing these sera,
5.7 The value of periodic meetings of the Directors of the WHO Collaborating 
Centres was stressed, and every effort should be made to schedule future 
meetings, perhaps in conjunction with technical conferences. The goal of 
meeting every two to three years was proposed.
